Aurinia Pharmaceuticals Inc.

NASDAQ:AUPH

Biotechnology

Healthcare
$15.13 +0.81%

+$0.13 today

Market cap
$2.03B
Beta
1.43
P/E (TTM)
7.2
EPS (TTM)
$2.25
52W Low $7.29High $16.88

Volume 0.76M

Average 1.21M

AUPH Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Aurinia Pharmaceuticals Inc.NASDAQ: AUPH

Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares declines year over year

Q2 FY2026 weighted avg shares of 130.08M shares fell 6.4% year over year, behind the -5.4% change in trailing-twelve-month weighted avg shares. Sequentially, it fell 1.7% from the prior quarter. Over 3 fiscal years it compounded at -1.8% a year.

Context

  • Weighted avg shares increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -6.4% toward the trailing-twelve-month pace of -5.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
130.08M-1.7% QoQ
Last fiscal yearDec 2025
134.37M-6.1% YoY
LTMJun 2026
133.21M-5.4% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-6.4%——
1 year-6.1%——
3-year CAGR-1.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
134.37M USD
Year-over-year change
-6.1%
4-year CAGR
+1.0%

Weighted Avg Shares vs competitors

How AUPH compares with its peers on the latest reported figures

  • AUPH's LTM Jun 2026 weighted avg shares of 133.21M shares is the highest of the 10 companies compared; the peer median is 67.85M shares.
  • Its year-over-year change of -5.4% is the lowest of 8, against a peer median of +31.1%.
  • Over three fiscal years its annual growth of -1.8% compares with a peer median of +34.1%.
AUPH Competitors Peer median
Weighted Avg Shares for AUPH and competitors
Company Period LTM YoY 3-year CAGR
AUPHAurinia Pharmaceuticals Inc.LTM Jun 2026133.21M -5.4%-1.8%
BHVNBiohaven Ltd.LTM Jun 2026131.06M +31.1%+34.0%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026124.17M +37.8%+23.4%
ALMSAlumis Inc. Common StockLTM Jun 2026115.39M +93.7%+384.0%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 202685.54M +48.0%+78.9%
VERAVera Therapeutics, Inc.LTM Jun 202667.85M +14.4%+34.2%
MLTXMoonLake ImmunotherapeuticsLTM Mar 202665.6M +4.1%+30.0%
ATTOAttovia Therapeutics, Inc.FY202543.03M +0.0%—
EVMNEvommune, Inc.LTM Mar 202631.7M ——
TRAXFirst Tracks Biotherapeutics IncFY20250 ——
Peer median (excluding AUPH) 67.85M+31.1%+34.1%

Competitors are the stored peer set for AUPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue45.61M134.03M175.51M235.13M283.06M
Cost of Revenue1.09M5.66M14.15M28.25M32.67M
Gross Profit44.51M128.37M161.37M206.89M250.39M
Gross Margin97.6%95.8%91.9%88.0%88.5%
Research & Development51.14M44.99M49.64M20.79M32.51M
Selling, General & Admin171.44M196.37M195.04M172.03M101.79M
Operating Expenses225.25M239.84M253.06M211.57M145.48M
Depreciation & Amortization2.76M2.71M11.65M19.45M9.27M
EBITDA(177.45M)(103.65M)(63.05M)31.73M127.76M
EBITDA Margin-389.1%-77.3%-35.9%13.5%45.1%
Operating Income(180.74M)(111.47M)(91.69M)(4.69M)104.91M
Operating Margin-396.3%-83.2%-52.2%-2.0%37.1%
Interest Income529K5.12M17M16.97M13.57M
Interest Expense002.78M4.84M4.33M
Other Income / Expenses529K5.12M14.22M12.14M9.24M
Income Before Tax(180.21M)(106.35M)(77.47M)7.45M114.16M
Pre-Tax Margin-395.1%-79.3%-44.1%3.2%40.3%
Income Tax Expense760K1.83M551K1.7M(173.05M)
Net Income(180.97M)(108.18M)(78.02M)5.75M287.2M
Net Margin-396.8%-80.7%-44.5%2.4%101.5%
EPS (Basic)(1.40)(0.76)(0.54)0.042.14
EPS (Diluted)(1.40)(0.76)(0.54)0.042.07
Weighted Avg Shares129.37M141.92M143.24M143.06M134.37M
Weighted Avg Shares (Diluted)129.37M141.92M143.24M146.19M138.7M

Aurinia Pharmaceuticals Inc.

NASDAQ:AUPH

Intrinsic Alpha fair value

Locked

Current Price

$15.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.